G Ital Cardiol (Rome). 2026 Feb;27(2):121-129. doi: 10.1714/4636.46469.
ABSTRACT
Despite the widespread use of lipid-lowering therapies, a significant proportion of patients with atherosclerotic cardiovascular disease fail to achieve the recommended LDL-cholesterol targets, thus remaining at high residual risk. Inhibition of cholesteryl ester transfer protein (CETP) has long been considered a pharmacological strategy, but has historically been hindered by clinical failures. Obicetrapib, a next-generation CETP inhibitor, has recently shown promising results in terms of efficacy and safety. This review critically examines the physiology of CETP, the negative outcomes of earlier CETP inhibitors, and the emerging evidence on obicetrapib, highlighting the potential role of this molecule in the treatment of hypercholesterolemia and in the secondary prevention of atherosclerotic cardiovascular disease.
PMID:41631332 | DOI:10.1714/4636.46469